ELAN Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.3B
-7.5%
1.4B
-0.2%
1.4B
+19.8%
1.1B
+0.6%
1.1B
Cost of Revenue
545.0M
-4.4%
570.0M
-2.7%
586.0M
+5.6%
555.0M
+4.7%
530.0M
Gross Profit
720.0M
-9.8%
798.0M
+1.7%
785.0M
+33.3%
589.0M
-3.0%
607.0M
Operating Expenses
637.0M
-6.7%
683.0M
+6.6%
641.0M
-17.0%
772.0M
+27.6%
605.0M
R&D
99.0M
+7.6%
92.0M
-5.2%
97.0M
+4.3%
93.0M
+4.5%
89.0M
SG&A
393.0M
-12.5%
449.0M
+17.8%
381.0M
+12.7%
338.0M
-3.7%
351.0M
Operating Income
83.0M
-27.8%
115.0M
-20.1%
144.0M
+178.7%
-183000000
-9250.0%
2.0M
EBITDA
263.0M
-10.8%
295.0M
-11.1%
332.0M
+72.0%
193.0M
-4.9%
203.0M
Net Income
18.0M
-66.7%
54.0M
-5.3%
57.0M
+120.7%
-276000000
-711.8%
-34000000
EPS (Basic)
$0.04
-63.6%
$0.11
+0.0%
$0.11
+119.6%
$-0.56
-700.0%
$-0.07
EPS (Diluted)
$0.04
-63.6%
$0.11
+0.0%
$0.11
+119.6%
$-0.56
-700.0%
$-0.07
Shares (Diluted)
506.5M
+0.1%
505.9M
-0.0%
506.0M
+3.3%
489.6M
-1.4%
496.8M
Elanco Animal Health (ELAN) — Financials